232 related articles for article (PubMed ID: 36557826)
1. Combination of Docking-Based and Pharmacophore-Based Virtual Screening Identifies Novel Agonists That Target the Urotensin Receptor.
Li N; Yin L; Chen X; Shang J; Liang M; Gao L; Qiang G; Xia J; Du G; Yang X
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557826
[TBL] [Abstract][Full Text] [Related]
2. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.
Flohr S; Kurz M; Kostenis E; Brkovich A; Fournier A; Klabunde T
J Med Chem; 2002 Apr; 45(9):1799-805. PubMed ID: 11960491
[TBL] [Abstract][Full Text] [Related]
3. Developing new PI3Kγ inhibitors by combining pharmacophore modeling, molecular dynamic simulation, molecular docking, fragment-based drug design, and virtual screening.
Zhu J; Sun D; Li X; Jia L; Cai Y; Chen Y; Jin J; Yu L
Comput Biol Chem; 2023 Jun; 104():107879. PubMed ID: 37182359
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist.
Cho NC; Seo SH; Kim D; Shin JS; Ju J; Seong J; Seo SH; Lee I; Lee KT; Kim YK; No KT; Pae AN
J Comput Aided Mol Des; 2016 Aug; 30(8):625-37. PubMed ID: 27600555
[TBL] [Abstract][Full Text] [Related]
6. Towards Targeting the Urotensinergic System: Overview and Challenges.
Nassour H; Iddir M; Chatenet D
Trends Pharmacol Sci; 2019 Oct; 40(10):725-734. PubMed ID: 31500846
[TBL] [Abstract][Full Text] [Related]
7. An investigation into the origin of the biased agonism associated with the urotensin II receptor activation.
Brancaccio D; Merlino F; Limatola A; Yousif AM; Gomez-Monterrey I; Campiglia P; Novellino E; Grieco P; Carotenuto A
J Pept Sci; 2015 May; 21(5):392-9. PubMed ID: 25694247
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
Sindhu T; Srinivasan P
Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
[TBL] [Abstract][Full Text] [Related]
9. Exploring Dual Agonists for PPARα/γ Receptors using Pharmacophore Modeling, Docking Analysis and Molecule Dynamics Simulation.
Ding TT; Liu YY; Zhang LM; Shi JR; Xu WR; Li SY; Cheng XC
Comb Chem High Throughput Screen; 2022; 25(9):1450-1461. PubMed ID: 34182904
[TBL] [Abstract][Full Text] [Related]
10. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
11. Rational approach to identify newer caspase-1 inhibitors using pharmacophore based virtual screening, docking and molecular dynamic simulation studies.
Patel S; Modi P; Chhabria M
J Mol Graph Model; 2018 May; 81():106-115. PubMed ID: 29549805
[TBL] [Abstract][Full Text] [Related]
12. Ensemble pharmacophore meets ensemble docking: a novel screening strategy for the identification of RIPK1 inhibitors.
Fayaz SM; Rajanikant GK
J Comput Aided Mol Des; 2014 Jul; 28(7):779-94. PubMed ID: 24980648
[TBL] [Abstract][Full Text] [Related]
13. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
[TBL] [Abstract][Full Text] [Related]
15. Urotensin receptor acts as a novel target for ameliorating fasting-induced skeletal muscle atrophy.
Yin L; Li N; Jia W; Wang N; Liang M; Shang J; Qiang G; Du G; Yang X
Pharmacol Res; 2022 Nov; 185():106468. PubMed ID: 36167277
[TBL] [Abstract][Full Text] [Related]
16. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors.
Hammad S; Bouaziz-Terrachet S; Meghnem R; Meziane D
J Mol Model; 2020 May; 26(6):160. PubMed ID: 32472293
[TBL] [Abstract][Full Text] [Related]
18. Development of Novel
Poret B; Desrues L; Bonin MA; Pédard M; Dubois M; Leduc R; Modzelewski R; Decazes P; Morin F; Vera P; Castel H; Bohn P; Gandolfo P
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32204509
[TBL] [Abstract][Full Text] [Related]
19. Structure-based pharmacophore modeling 1. Automated random pharmacophore model generation.
Szwabowski GL; Cole JA; Baker DL; Parrill AL
J Mol Graph Model; 2023 Jun; 121():108429. PubMed ID: 36804368
[TBL] [Abstract][Full Text] [Related]
20. Flexi-pharma: a molecule-ranking strategy for virtual screening using pharmacophores from ligand-free conformational ensembles.
Lans I; Palacio-Rodríguez K; Cavasotto CN; Cossio P
J Comput Aided Mol Des; 2020 Oct; 34(10):1063-1077. PubMed ID: 32656619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
